



Express Mail No.: EV 058427150 US 1648

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Young et al.

Serial No.: 09/996,265

Group Art Unit: 1648

Filed: November 28, 2001

Examiner: Chen, Stacy

For: METHODS OF
ADMINISTERING/DOSING ANTI-RSV
ANTIBODIES FOR PROPHYLAXIS
AND TREATMENT

Attorney Docket No.: 10271-048-999

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R.
§1.97 & §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the Patent and Trademark Office of all references coming to the attention of Applicants or their attorneys which are or may be related to patentability of the claimed invention, Applicants hereby direct the Examiner's attention to references **DV** to **FU**, which are listed on the accompanying revised PTO Form 1449. Copies of listed references **DV** to **FU** are provided herewith. Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application. While not to be construed as indicating that the Examiner should not review and consider fully all the listed references, Applicants particularly direct the Examiner's attention to references **DV**, **EI**, **ER**, and **ES**.

Identification of the listed references is not to be construed an admission by Applicants or their attorneys that such references are available as "prior art" against the subject application.

Pursuant to 37 C.F.R. §§ 1.97(c), Applicants estimate that a fee of \$180.00 is due in connection with the filing of this Information Disclosure Statement. Please charge the required fee to Jones Day Deposit Account No. 503013. A duplicate of this sheet is enclosed for accounting purposes.

Date March 8, 2004

Respectfully submitted,


Margaret B. Brivanlou 40,922
(Reg No.)

JONES DAY
222 E. 41st Street
New York, New York 10017-6702
(212) 790-9090



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY DOCKET NO.

10271-048-999

APPLICATION NO

09/996,265

APPLICANT

Young et al.

FILING DATE

November 28, 2001

GROUP

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DV	6,537,809	3/25/03	Brams			
	DW	6,096,551	8/1/00	Barbas et al.			
	DX	5,693,762	12/2/97	Queen et al.			
	DY	5,585,089	12/17/96	Queen et al.			
	FR	09/724,396		Young et al.			11/28/00
	FS	09/724,531		Young et al.			11/28/00
	FT	09/996,288		Young et al.			11/28/01
	FU	10/403,180		Young et al.			3/31/03

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	DZ	WO 00/29584	5/25/00	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

EA	Anderson et al., 1985, "Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay," J. Clin. Microbiol. 22:1050-1052
EB	Boulianne et al., 1984, "Production of functional chimaeric mouse/human antibody," Nature 312(5995):643-646
EC	Carson et al., 1986, "Human lymphocyte hybridomas and monoclonal antibodies," Adv. Immunol. 38:275-311
ED	Conrad et al., 1987, "Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic," Pediatr. Infect. Dis. J. 6(2):152-158
EE	Cruse et al., 1995, Illustrated Dictionary of Immunology, Boca Raton: CRC Press, pp. 18-19
EF	Dorland's Illustrated Medical Dictionary, 1994, 28 th ed., Philadelphia: WB Saunders p. 874
EG	Duenas et al., 1996, "In vitro immunization of naive human B cells yields high affinity immunoglobulin G antibodies as illustrated by phage display," Immunology 89:1-7
EH	Duenas et al., 1996, "Selection of phage displayed antibodies based on kinetic constants," Molecular Immunol. 33(3):279-285
EI	Everitt et al., 1996, "The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers," J. Infect. Dis. 174:463-469
EJ	Foote et al., 1995, "Kinetic and affinity limits on antibodies produced during immune response," Proc. Nat'l Acad. Science USA 92:1254-1256
EK	Foote et al., 1991, "Kinetic maturation of an immune response," Nature 352:530-532
EL	Glaser et al., 1992, "Antibody engineering by codon-based mutagenesis in a filamentous phage vector system," J. Immunol. 149:3903-3913
EM	Greenspan et al., 1999, "Defining epitopes: It's not as easy as it seems," Nature Biotechnology 17:936-937
EN	Groves et al., 1987, "Production of an ovine monoclonal antibody to testosterone by an interspecies fusion," Hybridoma 6(1):71-76

EO	Hall et al., 1985, "Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease," JAMA 254(21):3047-3051
EP	Hall et al., 1983, "Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study," N. Engl. J. Med. 308(24):1443-1447
EQ	Hall et al., 1975, "Nosocomial respiratory syncytial virus infections," N. Engl. J. Med. 293(26):1343-1346
ER	Haynes et al., 2002, "Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection," J. Virol. 76(14):6873-6881
ES	Johnson et al., 1999, "A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19," J. Infect. Dis. 180(1):35-40
ET	Karlsson et al., 1997, "Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors," J Immunol. Meth. 200:121-133
EU	Knappik et al., 2000, "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides," J. Mol. Biol. 296:57-86
EV	Liu et al., 1987, "Expression of mouse::human immunoglobulin heavy-chain cDNA in lymphoid cells," Gene 54(1):33-40
EW	LoBuglio et al., 1989, "Mouse/human chimeric monoclonal antibody in man: kinetics and immune response," Proc. Natl. Acad. Sci. USA 86(11):4220-4224
EX	Morrison et al., 1985, "Transfectomas provide novel chimeric antibodies," Science 229(4719):1202-1207
EY	Morrison et al., 1984, "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," Proc. Natl. Acad. Sci. USA 81(21):6851-6855
EZ	Myszka et al., 1999, "Survey of the 1998 optical biosensor literature," J. Mol. Recog. 12:390-408
FA	Newman et al., 1992, "'Primitization' of recombinant antibodies for immunotherapy of human diseases: A Macaque/Hunab chimeric antibody against human CD4," Biotechnol. 10:1455-1460
FB	Prince et al., 1996, "Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid," J. Infect. Dis. 173:598-608
FC	Raman et al., 1992, "Diffusion-limited rates for monoclonal antibody binding to cytochrome," Biochem. 31:10370-10379
FD	Roost et al., 1995, "Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity," PNAS USA 92:1257-1261
FE	Rosok et al., 1995, "A combinatorial library strategy for the rapid humanization of anticarcinoma BR 96 Fab," JBC 271(27):22611-22618
FF	Rudikoff et al., 1982, "Single amino acid substitution altering antigen-binding specificity," Proc. Natl. Acad. Sci. USA 79(6):1979-1983
FG	Sahagan et al., 1986, "A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen," J. Immunol. 137(3):1066-1074
FH	Schier et al., 1996, "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site," J. Mol. Biol. 263(4):551-567
FI	Steplewski et al., 1988, "Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity," Proc. Natl. Acad. Sci. USA 85(13):4852-4856
FJ	Sun et al., 1987, "Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A," Proc. Natl. Acad. Sci. USA 84(1):214-218
FK	Takeda et al., 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," Nature 314(6010):452-454
FL	Talwar et al., 1976, "Isoimmunization against human chorionic gonadotropin with conjugates of processed beta-subunit of the hormone and tetanus toxoid," Proc. Natl. Acad. Sci. USA 73(1):218-222
FM	van Wyke et al., 1985, "Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus," Virology 143(2):569-582
FN	Wald et al., 1988, "In re ribavirin: a case of premature adjudication?" J. Pediatr. 112(1):154-158
FO	Wright et al., 1982, "Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children," Infect. Immun. 37(1):397-400
FP	Wu et al., 1998, "Stepwise in vitro affinity maturation of Vitaxin, an avb-specific humanized mAb," PNAS 95:6037-6042
FQ	Geneseq Database, Accession no: AAW70933, entry date Oct. 1998 from patent no FR2758331-A1 of Bourgeois et al.

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

10271-048-999

APPLICATION NO

09/996,265

APPLICANT

Young et al.

FILING DATE

November 28, 2001

GROUP

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DV	6,537,809	3/25/03	Brams			
	DW	6,096,551	8/1/00	Barbas et al.			
	DX	5,693,762	12/2/97	Queen et al.			
	DY	5,585,089	12/17/96	Queen et al.			
	FR	09/724,396		Young et al.			11/28/00
	FS	09/724,531		Young et al.			11/28/00
	FT	09/996,288		Young et al.			11/28/01
	FU	10/403,180		Young et al.			3/31/03

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	DZ	WO 00/29584	5/25/00	PCT			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

EA	Anderson et al., 1985, "Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay," J. Clin. Microbiol. 22:1050-1052
EB	Boulianne et al., 1984, "Production of functional chimaeric mouse/human antibody," Nature 312(5995):643-646
EC	Carson et al., 1986, "Human lymphocyte hybridomas and monoclonal antibodies," Adv. Immunol. 38:275-311
ED	Conrad et al., 1987, "Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic," Pediatr. Infect. Dis. J. 6(2):152-158
EE	Cruse et al., 1995, Illustrated Dictionary of Immunology, Boca Raton: CRC Press, pp. 18-19
EF	Dorland's Illustrated Medical Dictionary, 1994, 28 th ed., Philadelphia: WB Saunders p. 874
EG	Duenas et al., 1996, "In vitro immunization of naïve human B cells yields high affinity immunoglobulin G antibodies as illustrated by phage display," Immunology 89:1-7
EH	Duenas et al., 1996, "Selection of phage displayed antibodies based on kinetic constants," Molecular Immunol. 33(3):279-285
EI	Everitt et al., 1996, "The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers," J. Infect. Dis. 174:463-469
EJ	Foote et al., 1995, "Kinetic and affinity limits on antibodies produced during immune response," Proc. Nat'l Acad. Science USA 92:1254-1256
EK	Foote et al., 1991, "Kinetic maturation of an immune response," Nature 352:530-532
EL	Glaser et al., 1992, "Antibody engineering by codon-based mutagenesis in a filamentous phage vector system," J. Immunol. 149:3903-3913
EM	Greenspan et al., 1999, "Defining epitopes: It's not as easy as it seems," Nature Biotechnology 17:936-937
EN	Groves et al., 1987, "Production of an ovine monoclonal antibody to testosterone by an interspecies fusion," Hybridoma 6(1):71-76

EO	Hall et al., 1985, "Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease," JAMA 254(21):3047-3051
EP	Hall et al., 1983, "Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study," N. Engl. J. Med. 308(24):1443-1447
EQ	Hall et al., 1975, "Nosocomial respiratory syncytial virus infections," N. Engl. J. Med. 293(26):1343-1346
ER	Haynes et al., 2002, "Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection," J. Virol. 76(14):6873-6881
ES	Johnson et al., 1999, "A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19," J. Infect. Dis. 180(1):35-40
ET	Karlsson et al., 1997, "Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors," J Immunol. Meth. 200:121-133
EU	Knappik et al., 2000, "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides," J. Mol. Biol. 296:57-86
EV	Liu et al., 1987, "Expression of mouse:human immunoglobulin heavy-chain cDNA in lymphoid cells," Gene 54(1):33-40
EW	LoBuglio et al., 1989, "Mouse/human chimeric monoclonal antibody in man: kinetics and immune response," Proc. Natl. Acad. Sci. USA 86(11):4220-4224
EX	Morrison et al., 1985, "Transfectomas provide novel chimeric antibodies," Science 229(4719):1202-1207
EY	Morrison et al., 1984, "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," Proc. Natl. Acad. Sci. USA 81(21):6851-6855
EZ	Myszka et al., 1999, "Survey of the 1998 optical biosensor literature," J. Mol. Recog. 12:390-408
FA	Newman et al., 1992, "'Primitization' of recombinant antibodies for immunotherapy of human diseases: A Macaque/Hunab chimeric antibody against human CD4," Biotechnol. 10:1455-1460
FB	Prince et al., 1996, "Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid," J. Infect. Dis. 173:598-608
FC	Raman et al., 1992, "Diffusion-limited rates for monoclonal antibody binding to cytochrome," Biochem. 31:10370-10379
FD	Roost et al., 1995, "Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity," PNAS USA 92:1257-1261
FE	Rosok et al., 1995, "A combinatorial library strategy for the rapid humanization of anticarcinoma BR 96 Fab," JBC 271(27):22611-22618
FF	Rudikoff et al., 1982, "Single amino acid substitution altering antigen-binding specificity," Proc. Natl. Acad. Sci. USA 79(6):1979-1983
FG	Sahagan et al., 1986, "A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen," J. Immunol. 137(3):1066-1074
FH	Schier et al., 1996, "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site," J. Mol. Biol. 263(4):551-567
FI	Steplewski et al., 1988, "Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity," Proc. Natl. Acad. Sci. USA 85(13):4852-4856
FJ	Sun et al., 1987, "Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen I7-1A," Proc. Natl. Acad. Sci. USA 84(1):214-218
FK	Takeda et al., 1985, "Construction of chimeric processed immunoglobulin genes containing mouse variable and human constant region sequences," Nature 314(6010):452-454
FL	Talwar et al., 1976, "Isoimmunization against human chorionic gonadotropin with conjugates of processed beta-subunit of the hormone and tetanus toxoid," Proc. Natl. Acad. Sci. USA 73(1):218-222
FM	van Wyke et al., 1985, "Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus," Virology 143(2):569-582
FN	Wald et al., 1988, "In re ribavirin: a case of premature adjudication?" J. Pediatr. 112(1):154-158
FO	Wright et al., 1982, "Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children," Infect. Immun. 37(1):397-400
FP	Wu et al., 1998, "Stepwise in vitro affinity maturation of Vitaxin, an avb-specific humanized mAb," PNAS 95:6037-6042
FQ	Geneseq Database, Accession no: AA W70933, entry date Oct. 1998 from patent no FR2758331-A1 of Bourgeois et al.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.